Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Update

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 3,940,000 shares, a decline of 13.6% from the June 30th total of 4,560,000 shares. Based on an average daily trading volume, of 456,400 shares, the days-to-cover ratio is currently 8.6 days.

Wall Street Analyst Weigh In

Several research firms recently issued reports on KNSA. Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, May 3rd. They issued an “overweight” rating and a $34.00 target price on the stock. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Evercore ISI upped their price objective on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $32.00.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 22,000 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $26.32, for a total transaction of $579,040.00. Following the sale, the insider now owns 47,803 shares of the company’s stock, valued at $1,258,174.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Sanj K. Patel sold 136,124 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the transaction, the chief executive officer now owns 63,012 shares in the company, valued at $1,616,257.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider John F. Paolini sold 22,000 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $26.32, for a total transaction of $579,040.00. Following the completion of the transaction, the insider now owns 47,803 shares in the company, valued at approximately $1,258,174.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 182,372 shares of company stock valued at $4,671,729. 54.57% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC grew its position in Kiniksa Pharmaceuticals by 0.5% in the 1st quarter. Essex Investment Management Co. LLC now owns 172,740 shares of the company’s stock worth $3,408,000 after purchasing an additional 850 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Kiniksa Pharmaceuticals by 5.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock valued at $413,000 after acquiring an additional 1,153 shares during the period. SG Americas Securities LLC grew its position in shares of Kiniksa Pharmaceuticals by 8.1% during the 1st quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after acquiring an additional 1,435 shares during the period. Los Angeles Capital Management LLC grew its position in shares of Kiniksa Pharmaceuticals by 1.1% during the 4th quarter. Los Angeles Capital Management LLC now owns 147,182 shares of the company’s stock valued at $2,582,000 after acquiring an additional 1,540 shares during the period. Finally, QRG Capital Management Inc. grew its position in shares of Kiniksa Pharmaceuticals by 11.7% during the 4th quarter. QRG Capital Management Inc. now owns 16,010 shares of the company’s stock valued at $281,000 after acquiring an additional 1,679 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Trading Up 0.5 %

Shares of KNSA traded up $0.12 on Wednesday, reaching $26.60. The company’s stock had a trading volume of 458,122 shares, compared to its average volume of 431,302. Kiniksa Pharmaceuticals has a twelve month low of $14.12 and a twelve month high of $27.88. The stock has a market capitalization of $1.89 billion, a PE ratio of 241.84 and a beta of 0.38. The firm has a fifty day moving average of $20.24 and a 200-day moving average of $19.58.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The company had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. During the same quarter in the prior year, the business posted ($0.02) EPS. The firm’s revenue was up 51.5% compared to the same quarter last year. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals will post -0.05 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.